Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921404 | 0.81 | GSK3A (0.53) | KMT2AALDH1A1SMN1; SMN2MEN1SIGMAR1 | |
| SCHEMBL31190634 | 0.79 | ELANE (0.48) | KMT2ALMNAALDH1A1MEN1SIGMAR1 | |
| SCHEMBL2661493 | 0.79 | CMA1 (0.52) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL9165337 | 0.75 | LMNA (0.54) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27721661 | 0.74 | LMNA (0.53) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2191407 | 0.74 | KMT2A (0.56) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23310509 | 0.72 | KMT2A (0.58) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1542663 | 0.72 | HSP90AA1 (0.71) | KMT2ALMNAALDH1A1SMN1; SMN2SIGMAR1 | |
| SCHEMBL9704359 | 0.71 | KMT2A (0.51) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8913952 | 0.70 | KMT2A (0.50) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | KMT2A 766/4885LMNA 1909/4885ALDH1A1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.